# Dose Escalation Study of Kylo-0603 in Healthy Subjects

> **NCT06365580** · PHASE1 · COMPLETED · sponsor: **Kylonova (Xiamen) Biopharma co., LTD.** · enrollment: 132 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Kylo-0603 capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06365580
- **Lead sponsor:** Kylonova (Xiamen) Biopharma co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-23
- **Primary completion:** 2024-08-16
- **Final completion:** 2024-08-16
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365580, "Dose Escalation Study of Kylo-0603 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06365580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*